182 related articles for article (PubMed ID: 33550434)
1. Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
Dai Y; Zhong F; Liu W; Song Q; Hu W
J Cancer Res Clin Oncol; 2021 May; 147(5):1379-1388. PubMed ID: 33550434
[TBL] [Abstract][Full Text] [Related]
2. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
3. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
[TBL] [Abstract][Full Text] [Related]
4. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia.
Widiasari NPA; Rai IBN; Dwi Kusumawardani IAJ; Sajinadiyasa IGK; Candrawati NW; Arisanti NLPE
Rom J Intern Med; 2023 Mar; 61(1):63-71. PubMed ID: 36453446
[No Abstract] [Full Text] [Related]
5. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Hsu KH; Huang YH; Tseng JS; Chen KC; Ku WH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Lung Cancer; 2019 Jan; 127():37-43. PubMed ID: 30642549
[TBL] [Abstract][Full Text] [Related]
6. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients.
Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM
Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633
[TBL] [Abstract][Full Text] [Related]
8. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.
Chen YY; Lin KH; Kuo YS; Tsai YM; Huang HK; Huang TW
World J Surg Oncol; 2023 Oct; 21(1):326. PubMed ID: 37833769
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
Ke SB; Qiu H; Chen JM; Shi W; Chen YS
Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
[TBL] [Abstract][Full Text] [Related]
11. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
12. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (
Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS
Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206
[TBL] [Abstract][Full Text] [Related]
13. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
14. The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma.
Huang YH; Hsu KH; Tseng JS; Chen KC; Hsu CH; Su KY; Chen JJW; Chen HW; Yu SL; Yang TY; Chang GC
Cancer Res Treat; 2018 Oct; 50(4):1294-1303. PubMed ID: 29334606
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment.
Hung HY; Tseng YH; Liao CM; Chen SY; Wu TP; Lee YC; Chen YM
Integr Cancer Ther; 2017 Mar; 16(1):126-131. PubMed ID: 27151582
[TBL] [Abstract][Full Text] [Related]
16. Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis.
Wang H; Zhang M; Tang W; Ma J; Wei B; Niu Y; Zhang G; Li P; Yan X; Ma Z
Cancer Biol Ther; 2018 Aug; 19(8):687-694. PubMed ID: 29565727
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of YAP1 in EGFR mutant lung adenocarcinoma prior to tyrosine kinase inhibitor therapy is associated with poor survival.
Hong SA; Jang SH; Oh MH; Kim SJ; Kang JH; Hong SH
Pathol Res Pract; 2018 Mar; 214(3):335-342. PubMed ID: 29487002
[TBL] [Abstract][Full Text] [Related]
18. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
19. Overall response to first-line tyrosine kinase inhibitor and second-line chemotherapy is predictive of survival outcome in epidermal growth factor receptor-mutated adenocarcinoma.
Kuo SC; Hsu PC; Chen CH; Yu CT; Wang CL; Chung FT; Lin SM; Lo YL; Chen TC; Liu CY; Yang CT
Chemotherapy; 2014; 60(3):201-10. PubMed ID: 25871639
[TBL] [Abstract][Full Text] [Related]
20. Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.
He X; You J; Ding H; Zhang Z; Cui L; Shen X; Bian X; Liu Y; Chen J
BMC Cancer; 2021 Feb; 21(1):132. PubMed ID: 33549061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
